#thyroideyedisease #TED #Amgen #Tepezza #Teprotumumab #Gravesophthalmopath #GravesEyeDisease #autoimmunedisorder #overactivethyroid #marketingauthorisation #MHRA #immunotherapy #insulinlikegrowthfactor1receptor #IGF1R #phase3OPTICtrial #OPTICtrial #proptosis
pharmatimes.com/news/amgens-...
pharmatimes.com/news/amgens-...
Amgen’s Tepezza granted marketing authorisation in the UK - PharmaTimes
Teprotumumab approved as first targeted treatment for thyroid eye disease
pharmatimes.com
May 13, 2025 at 8:36 AM